EUVIMEDEUVIMED entdecken
Crossref

Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity

Sora Q Kim, Jeonghoon Kim, Mulim Choi, Young Kim, Shin Kim, Kee-Hong Kim

Biochemical and Biophysical Research Communications · 2023

DOI: 10.1016/j.bbrc.2023.149164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2023. Verfasst von Sora Q Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition Science, Purdue University, West Lafayette, IN, 47907, USA. Hauptthemen laut MEDLINE: Sterol O-Acyltransferase, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A glucagon-like peptide 1 receptor agonist (GLP-1 RA) semaglutide was approved for the treatment of obesity by the Food and Drug Administration. However, it can cause gastrointestinal events at high doses, limiting its broader use. Combining drugs with multiple mechanisms of action could enhance the weight-reducing effects while minimizing side effects. To this end, we investigated the combined effects of semaglutide and avasimibe, an acyl-CoA:cholesterol acyltransferase 1 (ACAT1) inhibitor, on weight reduction in diet-induced obesity mice. Two cohorts of mice were used: In cohort 1, mice were fed a high-fat (HF) diet for 12 weeks and then randomly assigned to the vehicle, avasimibe [10 mg/kg body weight (BW)], semaglutide (0.4 mg/kg BW), or combination groups. The drugs were administered via subcutaneous (sc) injections on a daily basis. In cohort 2, mice were fed an HF diet for 8 weeks and randomly assigned to the same four groups, but avasimibe was administered at a dose of 20 mg/kg BW, and the drugs were administered every 3 days. In cohort 1, semaglutide initially reduced food intake initially, but this effect was diminished with prolonged administration. Avasimibe, on the other hand, did not affect food intake but prevented weight gain to a lesser extent than semaglutide. Importantly, the combination treatment resulted in the greatest percentage of body weight reduction, along with lower plasma glucose and leptin levels compared to the semaglutide single-treatment group. Cohort 2 confirmed that the superior weight loss in the combination group compared to the other three groups was largely due to a significant reduction in fat mass. Histological analysis of inguinal adipose tissue showed smaller adipocyte size across all treatment groups compared to the vehicle group, with no significant differences among the treatment groups. Collectively, these findings suggest combining semaglutide and avasimibe could be an effective approach to weight management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sterol O-AcyltransferaseDiabetes Mellitus, Type 2HumansMiceAnimalsRodentiaAcyltransferasesAcyl Coenzyme AObesityDietWeight LossGlucagon-Like Peptide 1Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsAcetamidesSulfonamides

Stichwörter der Autor:innen

AvasimibeDiet-induced obesityGlucagon-like peptide 1 receptor agonistSemaglutideWeight loss

Substanzen

Sterol O-AcyltransferaseAcyltransferasesAcyl Coenzyme AGlucagon-Like Peptide 1Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsavasimibeAcetamidesSulfonamides

Autor:innen und Institutionen

  • Department of Nutrition Science, Purdue University, West Lafayette, IN, 47907, USA.
  • EFIL BioScience Inc., Bando Ivyvalley, Cheonggyesan-ro, Soojeong-gu, Seongnam-si, Gyeonggi-do, 13105, Republic of Korea.
  • Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, CA, 90095, USA.
  • Department of Chemistry, New York University, New York, NY, 10003, USA.
  • Department of Food Science, Purdue University, West Lafayette, IN, 47907, USA. Electronic address: keehong@purdue.edu.

Zitieren

APA

Kim, S. Q., Kim, J., Choi, M., Kim, Y., Kim, S., & Kim, K. H. (2023). Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2023.149164

Vancouver

Kim SQ, Kim J, Choi M, Kim Y, Kim S, Kim KH. Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity. Biochemical and Biophysical Research Communications. 2023. doi:10.1016/j.bbrc.2023.149164

BibTeX
@article{Kim2023,
  author = {Kim, Sora Q and Kim, Jeonghoon and Choi, Mulim and Kim, Young and Kim, Shin and Kim, Kee-Hong},
  title = {Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity},
  journal = {Biochemical and Biophysical Research Communications},
  year = {2023},
  doi = {10.1016/j.bbrc.2023.149164}
}
Kostenlos starten →